Review

mouse breast cancer cell line 4t1 (ATCC)

ATCC is a verified supplier

ATCC manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

ATCC mouse breast cancer cell line 4t1

Synergistic antitumor efficacy of trivalent <t>SaPAC‐4T1</t> vaccination combined with anti‐PD‐1 checkpoint blockade in orthotopic 4T1 TNBC. (A) Treatment timeline. (B) Representative endpoint tumors (day 16; scale bar, 10 mm). (C) Longitudinal tumor volumes ( n = 6–8 mice/group). (D) Terminal tumor volumes on day 15. (E,F) Individual tumor growth trajectories. Data are the mean ± SEM; significance was assessed by unpaired two‐tailed Student's t‐test ( * p <0.05, ** p <0.01, *** p <0.001 vs. mock + anti‐PD‐1).

Mouse Breast Cancer Cell Line 4t1, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 6935 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+breast+cancer+cell+line+4t1/4T1/pmc13633104-231-17-26
Average 99 stars, based on 6935 article reviews

mouse breast cancer cell line 4t1 - by Bioz Stars, 2026-10

99/100 stars

Images

1) Product Images from "Self‐Assembling Peptide‐Adjuvant Conjugate (SaPAC) Platform for Precision Cancer Immunotherapy"

Article Title: Self‐Assembling Peptide‐Adjuvant Conjugate (SaPAC) Platform for Precision Cancer Immunotherapy

Journal: Advanced Science

doi: 10.1002/advs.77632

Synergistic antitumor efficacy of trivalent SaPAC‐4T1 vaccination combined with anti‐PD‐1 checkpoint blockade in orthotopic 4T1 TNBC. (A) Treatment timeline. (B) Representative endpoint tumors (day 16; scale bar, 10 mm). (C) Longitudinal tumor volumes ( n = 6–8 mice/group). (D) Terminal tumor volumes on day 15. (E,F) Individual tumor growth trajectories. Data are the mean ± SEM; significance was assessed by unpaired two‐tailed Student's t‐test ( * p <0.05, ** p <0.01, *** p <0.001 vs. mock + anti‐PD‐1).

Figure Legend Snippet: Synergistic antitumor efficacy of trivalent SaPAC‐4T1 vaccination combined with anti‐PD‐1 checkpoint blockade in orthotopic 4T1 TNBC. (A) Treatment timeline. (B) Representative endpoint tumors (day 16; scale bar, 10 mm). (C) Longitudinal tumor volumes ( n = 6–8 mice/group). (D) Terminal tumor volumes on day 15. (E,F) Individual tumor growth trajectories. Data are the mean ± SEM; significance was assessed by unpaired two‐tailed Student's t‐test ( * p <0.05, ** p <0.01, *** p <0.001 vs. mock + anti‐PD‐1).

Techniques Used: Two Tailed Test

Peptides, peptide‐adjuvant conjugates, and fluorescently labeled peptides used in this study. The antigen epitope, linker/self‐assembly residues, and 1V209‐conjugated lysines (K * ) are indicated in the sequence column.

Figure Legend Snippet: Peptides, peptide‐adjuvant conjugates, and fluorescently labeled peptides used in this study. The antigen epitope, linker/self‐assembly residues, and 1V209‐conjugated lysines (K * ) are indicated in the sequence column.

Techniques Used: Labeling, Sequencing, Conjugation Assay

Multiple Displacement Amplification:

Article Title: The Osteoblastic Microenvironment Determines the Fate of Breast Cancer Cells Disseminated in the Bone Marrow
Article Snippet: .. The human breast cancer cell lines MDA‐MB‐231 (MDA231; RRID: CVCL_0062) and MCF7 (RRID: CVCL_0031), the mouse breast cancer cell line 4T1, and the mouse osteoblast progenitor cell line MC3T3‐E1 (RRID: CVCL_0409) were obtained from the American Type Culture Collection (ATCC). .. MDA231 and 4T1 cells (RRID: CVCL_0125) were maintained in RPMI 1640 medium (Thermo Fisher, 11875093) supplemented with 10% fetal bovine serum (FBS; Thermo Fisher, 10270106); MCF7 cells were cultured in DMEM (Thermo Fisher, 11995065) supplemented with 10% FBS; and MC3T3‐E1 cells were cultured in α‐MEM (Thermo Fisher, 12571063) supplemented with 10% FBS.

Article Title: Targeting ENO1 reprograms macrophage polarization to trigger antitumor immunity and improves the therapeutic effect of radiotherapy
Article Snippet: .. The mouse colon cancer cell line CT26, mouse breast cancer cell line 4T1, human CRC cell lines (SW480, SW620, HCT116, LoVo and HT29) and human breast cancer cell lines (MDA-MB-468, BT-20, HS578T and SUM-159) were obtained from the ATCC. ..

Article Title: Surface-displayed cholesterol enhances penetration and anti-tumor activity of a platinum nanodrug by targeting NPC1L1-expressing cancer associated fibroblasts
Article Snippet: Leukocytes, erythrocytes, and thrombocytes were determined by a Veterinary hematology analyzer (Prokan, China). .. Mouse embryonic fibroblast cell line NIH-3T3, human breast cancer cell line MDA-MB-231, human hepatic stellate cell (LX-2), and mouse breast cancer cell line 4T1 were sourced from American Type Culture Collection (ATCC). .. Mouse pancreatic cancer cell line Panc-02 and Panc-02 taggedwith luciferasewerepurchased fromXiamen Immocell Biotechnology Co., Ltd.

Article Title: Mitochondrial preservation through the PKA–DRP1 axis empowers natural killer cells to resist acidic stress and retain cytotoxicity
Article Snippet: .. The human NK cell line NK-92MI, the human breast cancer cell line MDA-MB-231, and the mouse breast cancer cell line 4T1 were purchased from the American Type Culture Collection (Manassas, VA, USA). .. NK-92MI cells were cultured in Minimum Essential Medium Alpha (12561056, Gibco/Life Technologies, Grand Island, NY, USA) supplemented with 2 mM L-glutamine (25030081, Gibco/Life Technologies), 12.5% fetal bovine serum (12483020, Gibco/Life Technologies), 0.1 mM 2-mercaptoethanol (21985023, Gibco/Life Technologies), 1% penicillin/streptomycin (15140122, Gibco/Life Technologies), 0.02 mM folic acid (F8758, Sigma-Aldrich, St. Louis, MO, USA), and 0.2 mM inositol (I5125, Sigma-Aldrich).

Article Title: Mitochondrial preservation through the PKA-DRP1 axis empowers natural killer cells to resist acidic stress and retain cytotoxicity.
Article Snippet: .. The human NK cell line NK-92MI, the human breast cancer cell line MDA-MB-231, and the mouse breast cancer cell line 4T1 were purchased from the American Type Culture Collection (Manassas, VA, USA). .. NK-92MI cells were cultured in Minimum AR TIC LE IN PR ES S Essential Medium Alpha (Gibco/Life Technologies, Grand Island, NY, USA) supplemented with 2 mM L-glutamine (Gibco/Life Technologies), 12.5% fetal bovine serum (Gibco/Life Technologies), 0.1 mM 2-mercaptoethanol (Gibco/Life Technologies), 1% penicillin/streptomycin (Gibco/Life Technologies), 0.02 mM folic acid (Sigma-Aldrich, St. Louis, MO, USA), and 0.2 mM inositol (Sigma-Aldrich).

Article Title: Potentiating mild photothermal therapy via CDK12/13-mediated AKT suppression to orchestrate ferroptosis-apoptosis crosstalk for vaccine-like immunity.
Article Snippet: 1 Department of Laboratory Medicine, The Third Xiangya Hospital, Central South University, Changsha 410013, People’s Republic of China 2 Department of Laboratory Medicine, Xiangya School of Medicine, Central South University, Changsha 410013, People’s Republic of China 3 Department of Oncology, The Third Xiangya Hospital, Central South University, Changsha 410013, People’s Republic of China 4 Department of General Surgery, The Third Xiangya Hospital, Central South University, Changsha 410013, People’s Republic of China Abstract Background Mild photothermal therapy (MPTT) offers a safe thermal window but typically fails to trigger sufficient immunogenic inflammation for durable tumor control.. Reprogramming the “cold” tumor microenvironment into a pro-inflammatory state is essential for effective immunotherapy.. Methods We established a synchronized intervention strategy combining MPTT with CDK12/13 inhibition (SR4835) and TGF-β blockade (SB431542).

Cell Culture:

Article Title: Thymopentin enhances adenoviral oncolytic therapy by regulating macrophages and CD8 + T cells.
Article Snippet: .. Cell lines The mouse breast cancer cell line 4T1 (ATCC, CRL-2539), the mouse colorectal cancer cell line CT26 (ATCC, CRL-2638) and the human embryonic kidney cell line 293T (ATCC, CRL-3216) were cultured in DMEM supplemented with 10% FBS, 100 U/mL penicillin, 0.1 mg/mL streptomycin (Gibco), and the mouse hepatocellular carcinoma (HCC) cell line H22 (CCTCC, IM-M003) was cultured in RPMI 1640 medium (Life Technologies). ..

Image Search Results

Journal: Advanced Science

Article Title: Self‐Assembling Peptide‐Adjuvant Conjugate (SaPAC) Platform for Precision Cancer Immunotherapy

doi: 10.1002/advs.77632

Figure Lengend Snippet: Synergistic antitumor efficacy of trivalent SaPAC‐4T1 vaccination combined with anti‐PD‐1 checkpoint blockade in orthotopic 4T1 TNBC. (A) Treatment timeline. (B) Representative endpoint tumors (day 16; scale bar, 10 mm). (C) Longitudinal tumor volumes ( n = 6–8 mice/group). (D) Terminal tumor volumes on day 15. (E,F) Individual tumor growth trajectories. Data are the mean ± SEM; significance was assessed by unpaired two‐tailed Student's t‐test ( * p <0.05, ** p <0.01, *** p <0.001 vs. mock + anti‐PD‐1).

Article Snippet: The DC2.4 cell line, mouse bladder cancer cell line MB49, mouse melanoma cell line B16F10, and the mouse breast cancer cell line 4T1 were purchased from ATCC.

Techniques: Two Tailed Test

Journal: Advanced Science

Article Title: Self‐Assembling Peptide‐Adjuvant Conjugate (SaPAC) Platform for Precision Cancer Immunotherapy

doi: 10.1002/advs.77632

Figure Lengend Snippet: Peptides, peptide‐adjuvant conjugates, and fluorescently labeled peptides used in this study. The antigen epitope, linker/self‐assembly residues, and 1V209‐conjugated lysines (K * ) are indicated in the sequence column.

Article Snippet: The DC2.4 cell line, mouse bladder cancer cell line MB49, mouse melanoma cell line B16F10, and the mouse breast cancer cell line 4T1 were purchased from ATCC.

Techniques: Labeling, Sequencing, Conjugation Assay

Differential biodistribution of exosomes and protein in 4T1 tumors (Balb/c mice): I-131-labeled control exosomes (HEK293 exo), anti-mouse CD206 antibody (CD206 Ab), fusion protein (fusion P) containing targeting peptide and Fc-mIgG2b, and engineered exosomes (Engi. Exo) carrying targeting peptide were administered IV into 4T1 breast cancer-bearing animals; SPECT images were obtained 3 h after administration. ( A ) SPECT images showed the distribution of the agents in the primary tumors (white circles) and lungs (yellow rectangular areas). White arrows show possible metastatic foci. Fusion protein and engineered exosomes accumulated in the primary and metastatic tumors. We used rainbow color to depict the activity of I-131. Blue is the lowest and red is the highest activity of I-131. ( B ) Randomly selected lung H&E staining showed multiple metastatic foci (black arrows). ( C ) Presence of numerous CD206+ cells is seen in tumors (green cells). n = 2–3 animals per group. Ab = antibody, Engi = engineered, Exo = exosomes, HE = Hematoxylin and Eosin, P = protein, SPECT = single-photon emission computed tomography, H = heart.

Journal: Cancers

Article Title: Therapeutically Engineering Exosomes to Target CD206+ M2 Macrophages to Prevent the Development of Primary Tumors and Distal Metastases in Breast Cancers

doi: 10.3390/cancers18101619

Figure Lengend Snippet: Differential biodistribution of exosomes and protein in 4T1 tumors (Balb/c mice): I-131-labeled control exosomes (HEK293 exo), anti-mouse CD206 antibody (CD206 Ab), fusion protein (fusion P) containing targeting peptide and Fc-mIgG2b, and engineered exosomes (Engi. Exo) carrying targeting peptide were administered IV into 4T1 breast cancer-bearing animals; SPECT images were obtained 3 h after administration. ( A ) SPECT images showed the distribution of the agents in the primary tumors (white circles) and lungs (yellow rectangular areas). White arrows show possible metastatic foci. Fusion protein and engineered exosomes accumulated in the primary and metastatic tumors. We used rainbow color to depict the activity of I-131. Blue is the lowest and red is the highest activity of I-131. ( B ) Randomly selected lung H&E staining showed multiple metastatic foci (black arrows). ( C ) Presence of numerous CD206+ cells is seen in tumors (green cells). n = 2–3 animals per group. Ab = antibody, Engi = engineered, Exo = exosomes, HE = Hematoxylin and Eosin, P = protein, SPECT = single-photon emission computed tomography, H = heart.

Article Snippet: Syngeneic, aggressive triple-negative breast cancer (TNBC) mouse cell lines 4T1 (for Balb/c mice, ATCC, Manassas, VA, USA) and AT3 (for C57BL/6, Millipore, Burlington, MA, USA) were obtained and maintained in the laboratory in Dulbecco’s Modified Eagle Medium (DMEM) (Corning, Corning, NY, USA) supplemented with 10% fetal bovine serum (FBS) (Nalgene-GIBCO, Rochester, NY, USA), sodium pyruvate (GIBCO, Grand Island, NY, USA), non-essential amino acids (GIBCO), sodium glutamate (GIBCO), and 100 U/mL penicillin and streptomycin (GIBCO).

Techniques: Labeling, Control, Single Photon Emission Computed Tomography, Activity Assay, Staining

Resected model of breast cancer (4T1 in Balb/c mice) and metastasis: Representative images from tumor-resected animals (two from each group). All the primary tumors were resected 11 days after tumor cell implantation, and the animals were followed up to 63 days after resection. The figure shows representative animals from the control (HEK293 ( left panel )) and engineered exosome-treated ( right panel ) groups. The animals treated with the control exosomes began showing local recurrence and lung metastasis (black arrows show local recurrence and multiple distal metastases) starting on day 28 post-resection. None of the animals that received the engineered exosomes to deplete CD206+ cells showed any recurrence or distal metastasis. It is noteworthy that a small leftover tumor (white arrow) in one of the engineered exosome-treated animals disappeared following therapy on subsequent bioluminescent imaging. n = 5 per group. Pre-Sur = pre surgery, POD = post-operative day.

Journal: Cancers

Article Title: Therapeutically Engineering Exosomes to Target CD206+ M2 Macrophages to Prevent the Development of Primary Tumors and Distal Metastases in Breast Cancers

doi: 10.3390/cancers18101619

Figure Lengend Snippet: Resected model of breast cancer (4T1 in Balb/c mice) and metastasis: Representative images from tumor-resected animals (two from each group). All the primary tumors were resected 11 days after tumor cell implantation, and the animals were followed up to 63 days after resection. The figure shows representative animals from the control (HEK293 ( left panel )) and engineered exosome-treated ( right panel ) groups. The animals treated with the control exosomes began showing local recurrence and lung metastasis (black arrows show local recurrence and multiple distal metastases) starting on day 28 post-resection. None of the animals that received the engineered exosomes to deplete CD206+ cells showed any recurrence or distal metastasis. It is noteworthy that a small leftover tumor (white arrow) in one of the engineered exosome-treated animals disappeared following therapy on subsequent bioluminescent imaging. n = 5 per group. Pre-Sur = pre surgery, POD = post-operative day.

Techniques: Control, Imaging

Review

mouse breast cancer cell line 4t1 (ATCC)

Structured Review

Images

1) Product Images from "Self‐Assembling Peptide‐Adjuvant Conjugate (SaPAC) Platform for Precision Cancer Immunotherapy"

Related Articles

Multiple Displacement Amplification:

Cell Culture:

Similar Products

Image Search Results